Autologous Peripheral Blood Stem Cell Transplantation in First Remission Adult Acute Myeloid Leukaemia--An Intention to Treat Analysis and Comparison of Outcome Using a Predictive Model Based on the MRC AML10 Cohort

Joanne Ewing(Heart of England NHS Foundation Trust), R Chopra, Robert E. J. Ryder, J.H. Scarffe(The Christie Hospital), Jane Robertson(Cancer Research UK), G.R. Morgenstern, Alan K. Burnett(Cardiff University), William J. Kell(National Health Service), Joan Chang(University of Copenhagen)
Hematology
January 1, 2003
10.1080/1024533031000090793
Cited by 5

Related Papers

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
|Blood|2009|3.4k
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
|Blood|2010|1.9k
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
|Blood|2008|957
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)
|Blood|2007|782
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
|The Lancet Oncology|2014|703